Fig. 1: Gilteritinib inhibits AXL-positive solid tumor cell viability.
From: Antitumor activity of gilteritinib, an inhibitor of AXL, in human solid tumors
AXL protein expression in KYSE30, TE-1, A2780, SK-OV-3, HGC-27, and MKN45 cells was detected by western blot (A) and immunofluorescence staining (B). C Cells were treated with different concentrations of gilteritinib for 72 h, and the cell viability was measured by Cell Titer-Glo® Luminescent Cell Viability Assay. D Cells were treated with gilteritinib at the indicated concentrations. The cell confluency (%) was calculated using Incucyte S3 Zoom software based on phase-contrast images from 0 h to 72 h. Fluorescence images were obtained and analyzed with a laser confocal fluorescence microscope. Scale bars: 20 µm.
